← Back to all trials
Enrolling By Invitation
NCT07666386
Safety and Efficacy of B/F/TAF in Pregnancy
Conditions: HIV
Sex: Female
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 50
Sponsor: Shi Zou
Location: Zhongnan Hospital of Wuhan University Wuhan Hubei
Summary
This is a prospective, multicenter, observational study designed to evaluate the effectiveness and safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in pregnant women living with HIV. Given the limited prospective data on B/F/TAF use during early pregnancy, this study aims to address the evidence gap by observing women who are on B/F/TAF for at least six months with sustained viral suppression (HIV RNA \
Eligibility Criteria
Inclusion Criteria:
1. Women with aged 18 years or older and confirmed HIV infection.
2. Currently on B/F/TAF for 6 months preceding the screening visit.
3. Documented plasma HIV RNA\
Source: ClinicalTrials.gov (NCT07666386). StuddyBuddy aggregates publicly available trial information.
